May 15, 2018 / 10:14 AM / 6 months ago

BRIEF-Xenon Presents Positive Xen1101 Tms Pharmacodynamic Phase 1 Data At 14Th Eilat Conference

May 15 (Reuters) - Xenon Pharmaceuticals Inc:

* XENON PRESENTS POSITIVE XEN1101 TMS PHARMACODYNAMIC PHASE 1 DATA AT 14TH EILAT CONFERENCE

* XENON PHARMACEUTICALS INC - INITIATED A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED CROSS-OVER PHASE 1B TMS STUDY

* XENON PHARMACEUTICALS INC - PHASE 1B TMS STUDY DATA EXPECTED IN SECOND HALF OF 2018 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below